Gila Sellam

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA

Laurie H. Sehn, Maurizio Martelli, Marek Trněný et al. · Journal of Hematology & Oncology · 2020 · 134 citations · Full text

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

Shigeru Kusumoto, Luca Arcaini, Xiaonan Hong et al. · Blood · 2018 · 130 citations · Full text

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Magdalena Klánová, Laurie H. Sehn, Isabelle Bence‐Bruckler et al. · Blood · 2019 · 124 citations · Full text

Oral Sucrose and “Facilitated Tucking” for Repeated Pain Relief in Preterms: A Randomized Controlled Trial

Eva L. Cignacco, Gila Sellam, Lillian Stoffel et al. · PEDIATRICS · 2012 · 121 citations

Topical curcumin for the prevention of oral mucositis in pediatric patients: case series.

Elad Sharon, Irit Meidan, Gila Sellam et al. · PubMed · 2013 · 59 citations